Atlas Trials

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Clinical trial NCT04884191 · COMPLETED

Trial details

NCT number
NCT04884191
Sponsor
CTI BioPharma
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost- Essential Thrombocythemia Myelofibrosis
Start date
2017-07-31
Primary completion
2019-09-04
Enrollment
165

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.